Intellia Therapeutics price target lowered to $18 from $25 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Intellia Therapeutics (NTLA) to $18 from $25 and keeps a Buy rating on the shares. The FDA placed a clinical hold on nexiguran ziclumeran Phase 3 trials following the previously disclosed Grade 4 liver event, the analyst tells investors in a research note. The reduced the probability of approval to 30% from 40% for transthyretin amyloidosis indications.